EGFR and non-small cell lung carcinoma: Collectively, our findings revealed that clinical outcomes in NSCLC EGFR-mutant patients who were treated with EGFR TKIs were distinct, and imply that reproducible and reliable biomarkers that clearly predict treatment efficacy are crucial for the treatment of NSCLC EGFR-mutant patients.